ACER:NSD-Acer Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.85

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.02B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

USD55.27B 18.98 14.64
MRNA Moderna, Inc

N/A

USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD34.27B 36.37 33.83
SGEN Seagen Inc

N/A

USD33.25B 70.15 70.76
RPRX Royalty Pharma plc

N/A

USD32.48B 22.60 11.90
BGNE BeiGene, Ltd

N/A

USD31.01B N/A N/A
GMAB Genmab A/S

N/A

USD28.77B 26.59 3.08
BNTX BioNTech SE

N/A

USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACER

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 46.95% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.95% 93% A 96% A
Trailing 12 Months  
Capital Gain -11.09% 36% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.09% 36% F 25% F
Trailing 5 Years  
Capital Gain -80.22% 19% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.22% 18% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -1.58% 38% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.58% 38% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 74.20% 34% F 15% F
Risk Adjusted Return -2.13% 39% F 32% F
Market Capitalization 0.05B 10% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.91 71% C- 49% F
Price / Cash Flow Ratio -1.60 15% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -130.69% 21% F 8% F
Return on Invested Capital -94.23% 28% F 10% F
Return on Assets -66.68% 8% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.71 63% D 63% D
Short Percent 4.88% 60% D- 40% F
Beta 1.35 59% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.